Cardlytics, INC Form 4 insider transactions

Cardlytics' Chief Operating Officer, Amit Gupta, reports the acquisition and disposal of common stock and restricted stock units to cover tax obligations.

Cardlytics' Chief Legal & Privacy Officer, Lynton Nicholas Hollmeyer, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Director Liane Hornsey acquired 1,326 restricted stock units (RSUs) of Cardlytics, Inc. on April 9, 2024, which will vest in full on the one-year anniversary of the grant date.

Clifford Sosin, Managing Member of CAS Investment Partners, reports a pro rata distribution of Cardlytics (CDLX) shares from Sosin Master, L.P. to its partners.

Cardlytics' Chief Legal & Privacy Officer, Lynton Nicholas Hollmeyer, reports the vesting and sale of common stock to cover tax obligations.

Cardlytics CEO Karim Saad Temsamani reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Clifford Sosin, a director and 10% owner of Cardlytics, Inc., reports changes in beneficial ownership, including transactions involving convertible senior notes and common stock.

Cardlytics CEO Karim Saad Temsamani received 300,000 restricted stock units (RSUs) on March 22, 2024, according to a Form 4 filing with the SEC.

Nicholas Lynton, Chief Legal & Privacy Officer of Cardlytics, Inc., reports the acquisition of 85,035 restricted stock units (RSUs) on March 22, 2024.

Cardlytics' Chief Financial Officer, Alexis DeSieno, acquired 114,796 restricted stock units (RSUs) on March 22, 2024, according to a recent SEC filing.

Cardlytics' Chief Operating Officer, Amit Gupta, reports the acquisition of restricted stock units in the company.

Clifford Sosin, Managing Member of CAS Investment Partners, reports the acquisition of 350,000 shares of Cardlytics, Inc. at a price of $14.1601 per share.

Clifford Sosin, through CAS Investment Partners, has increased his firm's holdings in Cardlytics, Inc. (CDLX) with recent purchases of common stock.

Cardlytics CEO Karim Saad Temsamani sold shares of common stock on March 4, 2024, to cover withholding tax obligations related to the vesting of restricted stock units (RSUs).